Quitting smoking is one of the hardest health challenges many people face. Cigarettes contain nicotine, a substance that quickly creates addiction in the brain. Over time, the body begins to depend on nicotine, making it very difficult for smokers to stop even when they know the health risks.
Smoking is linked to many serious illnesses, including heart disease, lung cancer, stroke, and chronic lung disease. Because of these dangers, scientists and doctors have spent decades searching for better ways to help people quit.
According to global health statistics, smoking remains one of the leading causes of preventable death. In the United States alone, smoking causes about 480,000 deaths every year. Around the world, tobacco use is responsible for nearly 8 million deaths annually.
Many smokers want to quit, but the process is extremely challenging. Even when people use common treatments such as nicotine patches, nicotine gum, medications, or counseling, many relapse within months.
Researchers have therefore begun exploring completely new approaches to treat nicotine addiction. One of the most unusual options being studied is psilocybin, a psychedelic compound found in certain mushrooms often called “magic mushrooms.”
Psilocybin has been known for decades because of its strong effects on perception, mood, and thinking. In recent years, however, scientists have begun studying whether it might also help treat mental health conditions and addictions when used in controlled medical settings.
A new study published in the medical journal JAMA Network Open examined whether psilocybin could help people quit smoking more successfully than traditional treatments.
The research was carried out by scientists at Johns Hopkins University and conducted at the Johns Hopkins Bayview Medical Center. The trial ran for several years, from 2015 to 2023, and aimed to test whether psilocybin combined with therapy could help smokers break their addiction.
The researchers recruited 82 adult smokers who had previously tried to quit but had not succeeded. These participants were randomly placed into two different treatment groups. One group received a single high dose of psilocybin during a carefully supervised session. The other group followed a more traditional approach and used nicotine patches for eight to ten weeks.
Importantly, both groups also received the same psychological support through cognitive behavioral therapy, often called CBT. This type of therapy helps people understand their thoughts and behaviors and learn new strategies for dealing with cravings and stress.
Cognitive behavioral therapy is widely used in addiction treatment because it teaches patients how to recognize triggers that make them want to smoke and how to respond differently. By combining therapy with medication, doctors hoped to give both groups the best possible chance to quit.
Six months after the treatment began, the researchers evaluated how many participants had successfully stopped smoking. By this point, 38 people remained in the psilocybin group and 32 remained in the nicotine patch group. The results showed a striking difference between the two treatments.
Among those who received psilocybin, about 40.5 percent had completely stopped smoking for a long period of time. In comparison, only about 10 percent of the nicotine patch group had achieved the same result.
The researchers also looked at a shorter measure of success: whether participants had avoided smoking during the previous seven days. More than half of the psilocybin group passed this test, while only about one quarter of the nicotine patch group did.
The scientists also observed that participants in the psilocybin group smoked roughly half as many cigarettes per day during the study period compared with their previous habits. This suggests that even when people did not quit completely, their smoking was reduced significantly.
Interestingly, psilocybin appears to work very differently from traditional smoking treatments. Most medications designed to help smokers quit work by targeting nicotine receptors in the brain.
These drugs try to reduce cravings or mimic nicotine’s effects in a safer way. Psilocybin does not act directly on nicotine pathways. Instead, researchers believe it may change how people think about themselves, their habits, and their behaviors.
Some scientists believe psilocybin may increase psychological flexibility. This means it might help people step outside old patterns of thinking and behavior. In the case of addiction, this shift could allow individuals to see smoking differently and break the mental cycle that keeps them dependent on cigarettes.
The study reported that no serious medical problems occurred during the trial. Some participants experienced mild side effects such as headaches, nausea, or temporary increases in blood pressure. Because the psilocybin sessions were carefully supervised by trained professionals, safety was closely monitored.
While the findings are promising, the researchers also emphasized several limitations. The study was relatively small and included only 82 participants.
Many participants were highly educated and had previous experience with psychedelic substances, which may influence how people respond to psilocybin therapy. In addition, the trial was not fully blinded because the effects of psilocybin are very noticeable, making it difficult to hide which treatment participants received.
Despite these limitations, the results suggest that psychedelic therapy may represent a new direction in addiction treatment. If larger studies confirm these findings, psilocybin could become an important tool for helping smokers quit, especially for those who have struggled with traditional methods.
However, many questions remain. Scientists still need to determine the best dosage, how many therapy sessions are required, and whether the treatment would work for broader populations. Researchers must also evaluate the long‑term safety, cost, and accessibility of psychedelic therapies.
Overall, this study provides intriguing evidence that psilocybin may help people overcome nicotine addiction more effectively than standard nicotine replacement therapy in some cases. By targeting psychological patterns rather than only physical cravings, the treatment may offer a fresh strategy in the fight against smoking.
If future research confirms these results, psilocybin‑assisted therapy could become part of a new generation of treatments designed to help millions of smokers finally break free from addiction.
If you care about smoking, please read studies about smoking may increase heart disease risk by 200% and e-cigarette smoke may cause lung cancer and bladder disease.
For more health information, please see recent studies about the cause of weight gain after smoking cessation, and results showing smoking may cause white scars on the brain.
Copyright © 2026 Knowridge Science Report. All rights reserved.
